Abstract
Leukocyte telomere length (LTL) is a biomarker of biological aging, and has been associated with metabolic diseases such as type 2 diabetes (T2DM). Insufficient maternal vitamin D (25(OH)D) has also been associated with increased disease risk for many diseases and adverse later life outcomes. The association between maternal and cord blood total 25(OH)D and LTL was examined in mother-child pairs from the HAPO Hong Kong Field Centre, including 815 offspring at age (mean±SD) 6.96 ± 0.44 years. LTL was measured using real-time polymerase chain reaction and serum 25(OH)D2, 25(OH)D3 and 3-epi-25(OH)D3 were measured in maternal blood (at gestation 24-32 weeks) and cord blood by liquid chromatography-mass spectrometry. Children LTL at follow-up was significantly shorter in boys compared to girls (p<0.001) at age 7. Childhood LTL was positively associated with insulin sensitivity according to the Matsuda index after sex and age adjustment (β±SE=0.038±0.017, p=0.022). Multiple linear regression was used to evaluate the relationship between 25(OH)D levels and LTL, with covariate adjustments for child age, sex, body mass index (BMI), systolic blood pressure (SBP), exercise, gestational age, mode of delivery, and maternal age, SBP, parity, smoking, current parental DM status and pre-pregnancy BMI. Childhood LTL positively correlated with total maternal 25(OH)D concentrations (β±SE=0.003±0.001, p=0.001), maternal D3 (β±SE=0.003±0.001, p=0.002) and maternal D3 epimer (β±SE=0.138±0.042, p<0.001), and similar associations were noted for cord D3 epimer (β±SE=0.101±0.045, p=0.024) and cord total 25(OH)D (β±SE=0.1±0.05, p=0.048), even after covariates adjustments. Our findings suggest 25(OH)D, D3 and D3 epimer both in utero and at birth may impact on childhood LTLs, highlighting a potential link between maternal vitamin D and biological aging. Disclosure K. Wong: None. B. E. Metzger: None. W. Lowe: None. W. H. Tam: None. R. C. Ma: Other Relationship; Self; AstraZeneca, Medtronic, Research Support; Self; AstraZeneca, Bayer Healthcare Pharmaceuticals Inc., Novo Nordisk, Pfizer Inc., Sanofi-Aventis, Tricida, Inc. F. Cheng: None. D. Mao: None. C. K. P. Lim: Stock/Shareholder; Self; GemVCare Ltd. R. Wang: None. C. H. Tam: None. M. A. Joglekar: None. A. A. Hardikar: None. A. Jenkins: Advisory Panel; Self; Abbott Diabetes, Sanofi-Aventis, Other Relationship; Self; Amgen Inc., Research Support; Self; Abbott, International Diabetes Federation, JDRF, Medtronic, Mylan N. V.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
